See more : Housecom Corporation (3275.T) Income Statement Analysis – Financial Results
Complete financial analysis of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bucher Industries AG (0QQN.L) Income Statement Analysis – Financial Results
- Persistent Systems Limited (PERSISTENT.NS) Income Statement Analysis – Financial Results
- Sime Darby Property Berhad (5288.KL) Income Statement Analysis – Financial Results
- Taiwan Taxi Co.,Ltd. (2640.TWO) Income Statement Analysis – Financial Results
- Kakatiya Cement Sugar and Industries Limited (KAKATCEM.BO) Income Statement Analysis – Financial Results
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. The company was founded in 2015 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 386.00K | 538.00K | 5.07M |
| Cost of Revenue | -38.65K | 0.00 | 0.00 |
| Gross Profit | 424.65K | 538.00K | 5.07M |
| Gross Profit Ratio | 110.01% | 100.00% | 100.00% |
| Research & Development | 291.94M | 277.35M | 175.95M |
| General & Administrative | 80.42M | 92.80M | 48.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 80.42M | 92.80M | 48.32M |
| Other Expenses | 58.00K | -55.54M | -511.54M |
| Operating Expenses | 365.06M | 382.71M | 220.42M |
| Cost & Expenses | 365.06M | 382.71M | 220.42M |
| Interest Income | 10.80M | 9.51M | 1.64M |
| Interest Expense | 1.52M | 787.00K | 891.00K |
| Depreciation & Amortization | 22.58M | 17.62M | 13.18M |
| EBITDA | -355.35M | -384.49M | -718.88M |
| EBITDA Ratio | -92,060.10% | -71,466.54% | -14,233.27% |
| Operating Income | -364.67M | -402.11M | -734.38M |
| Operating Income Ratio | -94,474.87% | -74,741.08% | -14,493.31% |
| Total Other Income/Expenses | -14.79M | -787.00K | -522.48M |
| Income Before Tax | -379.46M | -402.89M | -732.95M |
| Income Before Tax Ratio | -98,305.44% | -74,887.36% | -14,465.15% |
| Income Tax Expense | 0.00 | 17.39M | 12.94M |
| Net Income | -379.46M | -402.89M | -732.95M |
| Net Income Ratio | -98,305.44% | -74,887.36% | -14,465.15% |
| EPS | -1.05 | -1.08 | -1.96 |
| EPS Diluted | -1.05 | -1.08 | -1.96 |
| Weighted Avg Shares Out | 361.81M | 373.24M | 373.24M |
| Weighted Avg Shares Out (Dil) | 361.81M | 373.24M | 373.24M |
Source: https://incomestatements.info
Category: Stock Reports